Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They presently have a $65.00 target price on the stock. Cantor Fitzgerald’s price target points to a potential upside of 43.65% from the stock’s previous close.

A number of other research firms have also recently weighed in on GPCR. Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday. They set an “overweight” rating and a $118.00 price objective on the stock. BMO Capital Markets lifted their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Finally, JMP Securities decreased their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $88.33.

Structure Therapeutics Trading Up 7.9 %

Shares of GPCR stock opened at $45.25 on Monday. Structure Therapeutics has a 12 month low of $26.61 and a 12 month high of $75.02. The company has a market cap of $2.11 billion, a P/E ratio of -54.44 and a beta of -3.52. The firm has a fifty day moving average price of $37.97 and a 200 day moving average price of $39.61.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts forecast that Structure Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently bought and sold shares of the business. Sandia Investment Management LP acquired a new position in Structure Therapeutics in the second quarter valued at $39,000. Quarry LP acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $79,000. Sectoral Asset Management Inc. purchased a new stake in Structure Therapeutics during the 4th quarter valued at approximately $139,000. ADAR1 Capital Management LLC acquired a new stake in Structure Therapeutics during the 4th quarter worth approximately $163,000. Finally, Sei Investments Co. purchased a new position in shares of Structure Therapeutics in the 2nd quarter valued at approximately $212,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.